Dry Eye Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented by Indication (Evaporative Dry Eye Syndrome v/s Aqueous Deficient Dry Eye Syndrome), By Product Type (Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, and Others), By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, and Ointments), By Type
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationDry Eye Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented by Indication (Evaporative Dry Eye Syndrome v/s Aqueous Deficient Dry Eye Syndrome), By Product Type (Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, and Others), By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, and Ointments), By Type
In the U.S., more than 120,000 are blind from glaucoma, accounting for 9% to 12% of all cases of blindness.
Growing Prevalence of Dry Eye Disease
Based on data from the National Health and Wellness Survey, 6.8 percent of the United States adult population (approximately 16.4 million people) have been diagnosed with DED.
Growing investment in Healthcare Industry
In January 2022, Sun Pharma announced the launch of dry eye treatment product named Cequa in Canada. It is the first dry eye disease treatment that is delivered with nanomicellar (NCELL) technology. This technology enhances the bioavailability as well as physiochemical stability of cyclosporine to raise ocular tissue penetration.
Recent Development
- Cequa (cyclosporine ophthalmic solution) 0.09% was launched by Sun Pharma in 2018 as a prescription medication for the treatment of dry eye syndrome. Cequa is a calcineurin inhibitor that works by reducing inflammation and increasing tear production. It is the first and only approved ophthalmic solution with a nanomicellar technology that helps to improve drug penetration and efficacy.
- Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% was launched by Kala Pharmaceuticals in 2020 as a prescription medication for the short-term treatment of the signs and symptoms of dry eye syndrome. Eysuvis is a corticosteroid that works by reducing inflammation and improving tear production. It is the first and only approved corticosteroid for the treatment of dry eye syndrome.
- Klarity-C (ascorbic acid 6% and glycyrrhetinic acid 1% ophthalmic solution) was launched by ImprimisRx in 2020 as a prescription medication for the treatment of dry eye syndrome. Klarity-C is a combination of two ingredients, ascorbic acid (vitamin C) and glycyrrhetinic acid, that work together to reduce inflammation and improve tear production.
- Klarity is a new over-the-counter dry eye syndrome medication that was launched in 2021. It is a preservative-free eye drop solution that contains hyaluronic acid, which is a naturally occurring substance in the body that helps to retain moisture. Klarity eye drops work by moisturizing the eyes and providing long-lasting relief from dry eye syndrome.
Market Segmentation
The Global Dry Eye Syndrome Treatment Market can be segmented by indication, product type, dosage form, type, distribution channel and by region. Based on indication, the market can be divided into Evaporative Dry Eye Syndrome and Aqueous Deficient Dry Eye Syndrome. Based on product type, the market can be differentiated into Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, and Others. Based on dosage form, the market can be grouped into Gels, Eye Solutions, Capsules & Tablets, Eye Drops, and Ointments. Based on Type, the market can be divided into Prescription and Over the Counter. Based on distribution channel, the market can be segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, United States dominated the global dry eye syndrome treatment market on account of growing demand for dry eye treatment in the country.
Recent Development
- In 2019 October, Sun Pharmaceutical Industries Ltd launched a product CEQUA for the treatment of dry eye syndrome in the U.S. and the highest concentration of cyclosporine for ophthalmic use which is approved by the U.S. FDA.
- In 2019 July, Novartis announced the completion of the successful acquisition of Xiidra 5%, the first and only prescription treatment approved to treat both signs and symptoms of dry eye by controlling the inflammation caused by the disease.
Market Players
Johnson & Johnson, AbbVie Inc., Bausch Health Companies Inc., Novartis AG, Sun Pharmaceuticals Industries Limited, Santen Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Oyster Point Pharma, Inc., Alcon Inc., GlaxoSmithKline plc. are some of the leading players operating in the Global Dry Eye Syndrome Treatment Market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | · By Indication · By Product Type · By Dosage Form · By Type · By Distribution Channel · By Region |
| Regional scope | North America; Europe; Asia Pacific; South America; Middle East & Africa |
| Country scope | United States; Canada; Mexico; France; Germany; United Kingdom; Italy; Spain; China; India; Japan; South Korea; Australia; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE |
| Key companies profiled | Johnson & Johnson, AbbVie Inc., Bausch Health Companies Inc., Novartis AG, Sun Pharmaceuticals Industries Limited, Santen Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Oyster Point Pharma, Inc., Alcon Inc., GlaxoSmithKline plc. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy